Document is current

Article History

Accepted: 12 October 2024

First Online: 7 November 2024

Declarations

:

: Not applicable for this literature review.

: H. J. Longhurst has received grants or contracts from CSL Behring, Intellia, and KalVista, consulting fees from CSL Behring, Intellia, KalVista, and Takeda, payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or education events from CSL Behring and Takeda, support for travel and/or attending meetings from CSL Behring, Intellia, KalVista, Pharming, and Takeda, has participated on a Data Safety Monitoring Board or Advisory Board for CSL Behring, Intellia, KalVista, and Takeda, has received equipment, materials, drugs, medical writing, gifts or other services from CSL Behring, Intellia, KalVista, and has held a leadership or fiduciary role in HAE International Scientific Steering Committees. L. Bouillet has received support for the medical writing of this manuscript which was funded by KalVista, has received consulting fees from Takeda, CSL Behring, BioCryst, and KalVista, payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or education events from Takeda and BioCryst, payment for expert testimony from Takeda, CSL Behring, Pharvaris, BioCryst, and KalVista, support for travel and/or attending meetings from Takeda and BioCryst, has participated on a Data Safety Monitoring Board or Advisory Board for Takeda, BioCryst, CSL Behring, KalVista, and Pharvaris, and is the vice-president of the Société Nationale Française de Médecine Interne (SNFMI). M. Cancian has received consulting fees from CSL Behring, Takeda, Pharvaris, KalVista, and BioCryst, payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or education events from KalVista, Takeda, and CSL Behring, and support for travel and/or attending meetings from CSL Behring and Takeda. V. Grivcheva-Panovska has received support for the medical writing of this manuscript which was funded by KalVista, consulting fees from Pharming NV, KalVista, Astria, and Takeda, payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or education events from Pharming NV, Takeda, BioCryst, and KalVista, travel grants from Pharming NV and Takeda, has participated on a Data Safety Monitoring Board or Advisory Board for Pharming NV, KalVista, Takeda, and Astria and has received medical writing assistance from Pharming NV, BioCryst, and KalVista. M Koleilat has received support for the medical writing of this manuscript which was funded by KalVista, and has received grants or contracts as a clinical trial site from KalVista. M. Magerl has received support for medical writing of this manuscript which was funded by KalVista, research funding as a study center investigator from KalVista, and payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or education events from CSL Behring, Shire/Takeda, Pharming Technologies, BioCryst, Novartis, Octapharma, KalVista, Intellia, and Pharvaris. S. Savic has received support for the present manuscript from KalVista, grants or contracts from Novartis, SOBI, and CSL Behring, consulting fees from Novartis, SOBI, CSL Behring, Takeda, KalVista, BioCryst, Pharming, Celdex, and AstraZeneca, payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or education events from Takeda, SOBI, Novartis, and KalVista, has received support for travel and/or attending meetings from Novartis, and has a leadership or fiduciary role for the British Society for Immunology. M. Stobiecki has received lecture and presentations honoraria and consulting fees from CSL Behring, Takeda/Shire, and BioCryst. R Tachdjian has received grants or contracts from Astria, Ionis, CSL Behring, BioCryst, Takeda, KalVista, and Pharvaris, consulting fees from BioCryst, CSL Behring, Pharming, Takeda, KalVista, and Ionis, payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or education events from BioCryst, CSL Behring, Pharming, Takeda, Ionis, Sanofi, Regeneron, AstraZeneca, and GlaxoSmithKline, and has participated on a Data Safety Monitoring Board or Advisory Board for Astria, BioCryst, CSL Behring, KalVista, Pharming, Takeda, and Ionis. B. Healy is an employee of ApotheCom, which received funding from KalVista Pharmaceuticals for the project and support for travel and/or meeting attendance from KalVista Pharmaceuticals. C. M. Yea and P. K. Audhya hold stock or stock options and are employees of KalVista Pharmaceuticals.